Michael Chappell, MD
Family Medicine · Greer, SCNPI 1326104878
Payments from drug & device makers
Across 139 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$271
- Amgen$253
- AbbVie$209
- Abbott$177
- Takeda Pharmaceuticals U.S.A., Inc.$125
- AstraZeneca$121
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,193100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $271 |
| Amgen | 16 | $253 |
| AbbVie(2 entities) | 12 | $209 |
| Abbott | 12 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $125 |
| AstraZeneca | 9 | $121 |
| GSK | 7 | $101 |
| Bayer | 6 | $93 |
| Novartis | 5 | $78 |
| Boehringer Ingelheim | 5 | $71 |
| Pfizer | 5 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $65 |
| Amarin Pharma, Inc. | 4 | $58 |
| Daiichi Sankyo Inc. | 2 | $55 |
| Astellas Pharma US Inc | 3 | $54 |
| Lilly USA, LLC | 4 | $50 |
| Dexcom, Inc. | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Johnson & Johnson | 2 | $33 |
| Boston Scientific | 2 | $29 |
| Exact Sciences | 2 | $27 |
| Merck | 2 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Intuity Medical Inc | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$2,193 in reported general payments places this provider in the 70th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 98 | $90,138 |
| EliquisApixaban | 75 | $80,669 |
| XareltoRivaroxaban | 88 | $73,046 |
| OzempicSemaglutide | 63 | $66,688 |
| JanuviaSitagliptin Phosphate | 77 | $56,497 |
| LinzessLinaclotide | 38 | $37,084 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $32,812 |
| MounjaroTirzepatide | 24 | $27,427 |
| TrulicityDulaglutide | 15 | $21,758 |
| FarxigaDapagliflozin Propanediol | 26 | $21,175 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $18,695 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $18,356 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $15,734 |
| RexultiBrexpiprazole | 11 | $15,170 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $13,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $71 | $90,13898 claims |
| PfizerEliquis | $69 | $80,66975 claims |
| MerckJanuvia, Janumet, Belsomra | $25 | $79,725112 claims |
| Johnson & JohnsonXarelto | $33 | $73,04688 claims |
| Novo NordiskOzempic | $271 | $66,68863 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $101 | $51,50777 claims |
| Lilly USA, LLCMounjaro, Trulicity | $50 | $49,18539 claims |
| AbbVieLinzess, Synthroid | $209 | $39,19673 claims |
| AstraZenecaFarxiga | $121 | $21,17526 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $21 | $15,17011 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $125 | $10,32312 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $10,14513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Greer
- William ByarsGreer$4.8M
- Ronald DegarmoGreer$188K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.